A Randomized Trial of Three Regimens to Prevent Tuberculosis in HIV-Infected Patients With Anergy
NCT00402610 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 332
Last updated 2008-10-24
Summary
INTRODUCTION. To evaluate the efficacy of three regimens of prophylactic therapy for tuberculosis in HIV-infected patients with anergy. METHODS. Prospective, multi-center, randomized, comparative, and open clinical trial. Anergy was defined as absence of induration in response to three antigens (PPD, Candida albicans and parotiditis antigen) applied by the Mantoux method. Patients were randomized into one of the following prophylactic treatment groups: isoniazid for six months (6H), rifampin plus isoniazid for three months (3RH), rifampin plus pyrazinamide for two months (2RZ) or no treatment (NT). After completion of treatment, patients were followed up for two years.
Conditions
- HIV Infections
- Tuberculosis
Interventions
- DRUG
-
isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment
Sponsors & Collaborators
-
Sociedad Andaluza de Enfermedades Infecciosas
lead NETWORK
Principal Investigators
-
Antonio Rivero, MD PhD · Hospital Universitario Reina Sofía, Córdoba, Spain
-
Luis Lopez-Crtés, MD, PhD · Hospital Universitario Virgen del Rocío, Sevilla, Spain
-
Rafael Castillo, MD · 3 Sección de Enfermedades Infecciosas. Hospital Clínico Universitario San Cecilio. Avda. Dr. Oloriz 16. 18012 Granada
-
José Verdejo, MD · Servicio de Enfermedades Infecciosas. Hospital Carlos III. Sinesio Delgado 10. 28029 Madrid
-
Miguel Angel García, MD · Sección de Enfermedades Infecciosas. Hospital Carlos Haya. Avda. Carlos Haya s/n. 29010 Málaga.
-
Felipes Diez, MD · Servicio de Medicina Interna. Hospital Torrecárdenas. Paraje de Torrecárdenas s/n. 04009 Almería.
-
Jose Carlos Escribano, MD · Sección de Enfermedades Infecciosas. Hospital Universitario Puerta del Mar. Avda. Ana de Viya, 21. 11009 Cádiz. Spain
-
Jesús Canueto, MD · Sección de Enfermedades Infecciosas. Hospital Punta Europa de Algeciras. Ctra de Getares s/n. 11207 Algeciras (Cádiz)., Spain
-
Manuel Marquez, MD · Unidad de Enfermedades Infecciosas. Hospital Universitario Virgen de la Victoria, Campus Universitario Teatinos s/n. 29010 Málaga.
-
Juan Jose Hernandez, MD · Unidad de Enfermedades Infecciosas. Hospital Ciudad de Jaén, Avda del Ejército Español, 10. 23007 Jaén, Spain.
-
Juan Pasquau, MD · Sección de Enfermedades Infecciosas. Hospital Universitario Virgen de las Nieves. Avda de las Fuerzas Armadas, 2. 18014 Granada, Spain.
-
Fernando Lozano, MD PhD · Sección de Enfermedades Infecciosas. Hospital Universitario Virgen de Valme. Ctra. de Cádiz s/n. 41012 Sevilla, Spain
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1994-01-31
- Completion
- 1998-12-31
Countries
- Spain
Study Locations
More Related Trials
-
Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
NCT05081401 ·Status: RECRUITING ·Phase: PHASE3
-
Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)
NCT07163143 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Preventive Therapy for Tuberculosis in HIV Infected Persons
NCT00351702 ·Status: COMPLETED ·Phase: PHASE3
-
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
NCT02409290 ·Status: COMPLETED ·Phase: PHASE3
-
The Treatment of Tuberculosis in HIV-Infected Patients
NCT00001033 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
NCT00000796 ·Status: COMPLETED ·Phase: NA
-
Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB
NCT04752592 ·Status: COMPLETED ·Phase: NA
-
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
NCT06114628 ·Status: RECRUITING ·Phase: PHASE2
-
RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection
NCT03281226 ·Status: UNKNOWN ·Phase: PHASE2
-
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
NCT01601626 ·Status: TERMINATED ·Phase: PHASE2
-
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
NCT05118490 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3
NCT02057796 ·Status: COMPLETED ·Phase: PHASE4
-
Tuberculosis Treatment Shortening Trial
NCT00130247 ·Status: COMPLETED ·Phase: PHASE3
-
Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals
NCT03785106 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients
NCT06709157 ·Status: NOT_YET_RECRUITING
-
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial
NCT05017324 ·Status: UNKNOWN ·Phase: NA
-
TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)
NCT00107887 ·Status: COMPLETED ·Phase: PHASE4
-
Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)
NCT01875952 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis
NCT00698334 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
NCT04930744 ·Status: COMPLETED ·Phase: PHASE2
-
Diagnostic Trial to Validate the Use of the E-Nose in Pulmonary TB
NCT02768909 ·Status: UNKNOWN ·Phase: NA
-
Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness
NCT00931736 ·Status: COMPLETED ·Phase: PHASE3
-
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort
NCT06081361 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease
NCT05021731 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
NCT05413551 ·Status: COMPLETED ·Phase: PHASE1